A new scientific article has been published

Date: 2023-01-04

In the prestigious journal Alzheimer's Research & Therapy, Alzinova presents preclinical results demonstrating that the ALZ-201 antibody has specificity for the toxic oligomers that are central to the onset and development of Alzheimer's disease.

Furthermore, the research shows that ALZ-201 has the potential to be “best-in-class” in the clinic with good efficacy and more favourable side-effect profile compared to other candidates.

Read the press release

Link to Alzheimer’s Research & Therapy article